NASDAQ:MNOV MediciNova (MNOV) Stock Price, News & Analysis $1.31 +0.01 (+0.77%) (As of 07/26/2024 ET) Add Compare Share Share Today's Range$1.29▼$1.3550-Day Range$1.28▼$1.4752-Week Range$1.26▼$2.56Volume8,005 shsAverage Volume38,905 shsMarket Capitalization$64.26 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsStock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends Get MediciNova alerts: Email Address MediciNova MarketRank™ Stock AnalysisAnalyst RatingN/AUpside/DownsideN/AShort InterestBearish0.23% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.83Based on 2 Articles This WeekInsider TradingN/AProj. Earnings GrowthDecreasingFrom ($0.23) to ($0.24) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.0.11 out of 5 starsMedical Sector928th out of 936 stocksPharmaceutical Preparations Industry433rd out of 436 stocks N/A Analyst's Opinion Consensus RatingThere is not enough analysis data for MediciNova.Read more about MediciNova's stock forecast and price target. Previous Next 2.0 Short Interest Percentage of Shares Shorted0.23% of the float of MediciNova has been sold short.Short Interest Ratio / Days to CoverMediciNova has a short interest ratio ("days to cover") of 5.Change versus previous monthShort interest in MediciNova has recently increased by 6.03%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldMediciNova does not currently pay a dividend.Dividend GrowthMediciNova does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for MNOV. Previous Next 2.7 News and Social Media Coverage News SentimentMediciNova has a news sentiment score of 0.83. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.61 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 2 news articles for MediciNova this week, compared to 1 article on an average week.Search InterestOnly 1 people have searched for MNOV on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Previous Next 0.8 Company Ownership Insider Buying vs. Insider SellingIn the past three months, MediciNova insiders have not sold or bought any company stock.Percentage Held by Insiders14.90% of the stock of MediciNova is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 9.90% of the stock of MediciNova is held by institutions.Read more about MediciNova's insider trading history. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for MediciNova are expected to decrease in the coming year, from ($0.23) to ($0.24) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of MediciNova is -7.71, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of MediciNova is -7.71, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioMediciNova has a P/B Ratio of 1.03. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about MediciNova's valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Colonial MetalsCollapse of the PetrodollarThe death of the "petrodollar" seems imminent. And the implications could not be worse for Americans. Russia, China and India have decided to abandon the petrodollar.In answer to this issue, we have released a Special Report to the public. About MediciNova Stock (NASDAQ:MNOV)MediciNova, Inc., a biopharmaceutical company, focuses on developing novel and small molecule therapeutics for the treatment of serious diseases with unmet medical needs in the United States. It is developing MN-166 (ibudilast), an oral anti-inflammatory and neuroprotective agent for treating neurological and other disorders, such as primary and secondary progressive multiple sclerosis, amyotrophic lateral sclerosis, chemotherapy-induced peripheral neuropathy, degenerative cervical myelopathy, glioblastoma, and substance dependence and addiction, as well as prevention of acute respiratory distress syndrome, and long COVID. The company's product pipeline also includes MN-221 (bedoradrine), a selective beta-2-adrenergic receptor agonist for the treatment of acute exacerbations of asthma; MN-001 (tipelukast), an orally bioavailable small molecule compound to treat fibrotic and other diseases, including nonalcoholic fatty liver disease and idiopathic pulmonary fibrosis; and MN-029 (denibulin), a tubulin binding agent for treating solid tumor cancers. It has license agreements with Kyorin Pharmaceutical Co., Ltd; Angiogene Pharmaceuticals, Ltd.; and Meiji Seika Kaisha, Ltd. The company was incorporated in 2000 and is headquartered in La Jolla, California.Read More MNOV Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart MNOV Stock News HeadlinesJuly 26 at 1:27 AM | americanbankingnews.comMediciNova (NASDAQ:MNOV) Earns Hold Rating from Analysts at StockNews.comJuly 19, 2024 | americanbankingnews.comMediciNova (NASDAQ:MNOV) Now Covered by Analysts at StockNews.comJuly 26, 2024 | Crypto Swap Profits (Ad)625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetched, but results like this are within reach with the right knowledge and timing in the altcoin market. Plus, you’ll get $10 in real Bitcoin when you stay to the end of the call and take a short quiz.June 20, 2024 | globenewswire.comMediciNova Chief Business Officer David H. Crean, Ph.D.June 5, 2024 | globenewswire.comMediciNova Receives Notice of Allowance for New Patent Covering MN-166 (ibudilast) for the Prevention of Metastasis of Various Solid CancerJune 3, 2024 | globenewswire.comMediciNova Announces Data from Phase 1b/2a Clinical Trial of MN-166 (ibudilast) in Glioblastoma Patients at the American Society of Clinical Oncology (ASCO) Annual Meeting 2024May 28, 2024 | globenewswire.comMediciNova Announces Two Poster Presentations at the 92nd EAS Congress 2024, the Annual Meeting of the European Atherosclerosis Society Regarding the Use of MN-001 (Tipelukast) for Cardiometabolic ConditionsMay 20, 2024 | stockhouse.comMediciNova Receives Notice of Allowance for New Patent Covering MN-166 (ibudilast) for the Prevention of Metastasis of Eye CancerJuly 26, 2024 | Crypto Swap Profits (Ad)625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetched, but results like this are within reach with the right knowledge and timing in the altcoin market. Plus, you’ll get $10 in real Bitcoin when you stay to the end of the call and take a short quiz.May 20, 2024 | globenewswire.comMediciNova Receives Notice of Allowance for New Patent Covering MN-166 (ibudilast) for the Prevention of Metastasis of Eye CancerMay 14, 2024 | globenewswire.comMediciNova Receives Notice of Allowance for New Patent Covering MN-166 (ibudilast) for the Treatment of Chlorine-Induced Acute Respiratory Distress SyndromeMay 7, 2024 | finanznachrichten.deMediciNova, Inc.: MediciNova Receives Issue Notification for New Patent Covering Extended-Release Formulations of MN-166 (ibudilast)May 7, 2024 | globenewswire.comMediciNova Receives Issue Notification for New Patent Covering Extended-Release Formulations of MN-166 (ibudilast)April 30, 2024 | finance.yahoo.comMediciNova (NASDAQ:MNOV) investors are sitting on a loss of 89% if they invested five years agoApril 2, 2024 | globenewswire.comMediciNova Announces Abstract Regarding Results of a Clinical Trial of MN-166 (ibudilast) in Glioblastoma Accepted for Presentation at the 2024 American Society of Clinical Oncology Annual Meeting (2024 ASCO)March 27, 2024 | finanznachrichten.deMediciNova, Inc.: MediciNova Receives a Notice of Allowance for a New Patent Covering MN-166 (ibudilast) for the Treatment of Macular Injury in JapanMarch 27, 2024 | msn.comPre-market Movers: IBIO, DRCT, NUVB, PAYS, LUXH…March 27, 2024 | marketwatch.comMediciNova Gets Patent in Japan for Multiple Sclerosis-Related TreatmentSee More Headlines Receive MNOV Stock News and Ratings via Email Sign-up to receive the latest news and ratings for MediciNova and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/09/2024Today7/26/2024Next Earnings (Estimated)8/14/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:MNOV CUSIPN/A CIK1226616 Webmedicinova.com Phone(858) 373-1500Fax858-404-0048Employees10Year Founded2000Profitability EPS (Most Recent Fiscal Year)($0.17) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-8,560,000.00 Net MarginsN/A Pretax Margin-840.50% Return on Equity-13.35% Return on Assets-12.64% Debt Debt-to-Equity RatioN/A Current Ratio19.07 Quick Ratio19.07 Sales & Book Value Annual Sales$1 million Price / Sales64.26 Cash FlowN/A Price / Cash FlowN/A Book Value$1.27 per share Price / Book1.03Miscellaneous Outstanding Shares49,050,000Free Float41,738,000Market Cap$64.26 million OptionableOptionable Beta0.72 Social Links Beginners Guide To Retirement StocksClick the link below and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio. Get This Free Report Key ExecutivesDr. Yuichi Iwaki M.D. (Age 74)Ph.D., Co-Founder, President, CEO & Executive Director Comp: $933.05kDr. Kazuko Matsuda M.D. (Age 58)M.P.H., Ph.D., Chief Medical Officer & Director Comp: $653.65kMr. Jason J. Kruger CPA (Age 46)CFO & Principal Financial Officer Dr. David H. Crean M.B.A. (Age 59)Ph.D., Chief Business Officer Mr. John O'Neil CPAControllerKey CompetitorsHookipa PharmaNASDAQ:HOOKKezar Life SciencesNASDAQ:KZRNextCureNASDAQ:NXTCVerastemNASDAQ:VSTMVYNE TherapeuticsNASDAQ:VYNEView All Competitors MNOV Stock Analysis - Frequently Asked Questions How have MNOV shares performed this year? MediciNova's stock was trading at $1.50 at the start of the year. Since then, MNOV shares have decreased by 12.7% and is now trading at $1.31. View the best growth stocks for 2024 here. How were MediciNova's earnings last quarter? MediciNova, Inc. (NASDAQ:MNOV) announced its quarterly earnings data on Thursday, May, 9th. The biopharmaceutical company reported ($0.06) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.05) by $0.01. How do I buy shares of MediciNova? Shares of MNOV stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of MediciNova own? Based on aggregate information from My MarketBeat watchlists, some other companies that MediciNova investors own include Dynavax Technologies (DVAX), VBI Vaccines (VBIV), OPKO Health (OPK), Iovance Biotherapeutics (IOVA), Novavax (NVAX), Rigel Pharmaceuticals (RIGL) and Trevena (TRVN). This page (NASDAQ:MNOV) was last updated on 7/26/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | Sponsored“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 sp...Unstoppable Prosperity | SponsoredThis student turned $1,300 into $45,000 in just 4 Months!With the help of S.A.M. (my new AI-powered scanner) it's now easier than ever to find these unique trades... ...Monument Traders Alliance | SponsoredRare signal predicts 50% market drop - before electionThe market is near all-time highs, we're told that unemployment is low, AI's a gift to humanity, and the FED w...Behind the Markets | SponsoredMust-See: Elon’s New Invention is Absolutely InsaneCould Elon's New Device be Bigger than the iPhone? According to 30-year Silicon Valley and Wall Street vete...InvestorPlace | SponsoredElon to Transform U.S. Economy? A radical, potentially game-changing technology that threatens to destroy the trillion-dollar, “green energy” ...Porter & Company | Sponsored5 Stocks that could triple in a week Robinhood traders have piled $78 billion into this market... Driving tiny tech stock gains of 3,000%, 8,942...Traders Agency | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding MediciNova, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share MediciNova With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.